InMed Pharmaceuticals (NASDAQ: INM), a leader in the manufacturing and clinical development of rare cannabinoids, has released its financial results and corporate update for FY 2021. In addition, the company announced a conference call and webcast, in which company leadership will discuss the report. Interested parties can access a replay of the webcast for 90 days. Corporate highlights of the report include the definitive agreement the company entered to acquire BayMedica Inc., a private company specializing in the manufacture and commercialization of rare cannabinoids; the announcement that INM’s IntegraSyn(TM) cannabinoid manufacturing approach had achieved a level of 2g/L cannabinoid yield, a signal of commercial viability; and the filing of clinical trial applications in multiple countries for the company’s multisite Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (“EB”). In addition, the company noted that it had notified the Toronto Stock Exchange about the voluntary delisting of its common shares, which were delisted in May 2021. INM also entered into a securities purchase agreement with an institutional investor designed raise an estimated $12.0 million; INM closed the private placement on July 2, 2021. The company also reported a net loss of $10.2 million compared with a net loss of $8.9 million for the previous year, along with cash, cash equivalents and short-term investments totaling $7.4 million, compared to $5.8 million last year. “In the final quarter of our fiscal year 2021, as well as throughout the year, we made important progress in corporate development, pharmaceutical drug development and in advancing our proprietary manufacturing approach, IntegraSyn,” said InMed CEO Eric A. Adams in the press release. “With the recent announcements regarding our acquisition of BayMedica Inc., the Company is well positioned to continue its activities to solidify a leadership position in the field of rare cannabinoids.”
To view the full press releases, visit https://ibn.fm/K4Er0
About InMed Pharmaceuticals Inc.
InMed Pharmaceuticals is a clinical-stage pharmaceutical company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”); the company is developing IntegraSyn(TM) to produce pharmaceutical-grade cannabinoids. INM is dedicated to delivering new therapeutic alternatives to patients who may benefit from cannabinoid-based medicines. For more information, please visit www.InMedPharma.com.
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://ibn.fm/INM
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
